期刊
CANCER RESEARCH
卷 73, 期 20, 页码 6243-6253出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-12-4502
关键词
-
类别
资金
- Third Term Comprehensive Control Research for Cancer from the Ministry of Health, Labour and Welfare in Japan
- Japan Society for the Promotion of Science (JSPS)
- Grants-in-Aid for Scientific Research [24650646, 23790425, 23300350, 25462190] Funding Source: KAKEN
EGF receptor (EGFR) kinase inhibitors, including gefitinib and erlotinib, exert potent therapeutic efficacy in non-small cell lung cancers harboring EGFR-activating mutations. However, most patients ultimately develop resistance to these drugs. Here, we report a novel mechanism of acquired resistance to EGFR tyrosine kinase inhibitors and the reversal of which could improve clinical outcomes. In erlotinib-resistant lung cancer cells harboring activating EGFR mutations that we established, there was increased expression of Src, integrin beta 1, alpha 2, and alpha 5 along with enhanced cell adhesion activity. Interestingly, RNAi-mediated silencing of integrin beta 1 restored erlotinib sensitivity and reduced activation of Src and Akt after erlotinib treatment. Furthermore, Src silencing inhibited Akt phosphorylation and cell growth, with this inhibitory effect further augmented by erlotinib treatment. Increased expression of integrin beta 1, alpha 5, and/or alpha 2 was also observed in refractory tumor samples from patients with lung cancer treated with erlotinib and/or gefitinib. Together, our findings identify the integrin beta 1/Src/Akt signaling pathway as a key mediator of acquired resistance to EGFR-targeted anticancer drugs. Cancer Res; 73(20); 6243-53. (C) 2013 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据